Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP)

AIDS

Volumn 25, Issue 13, 2011, Pages 1575-1583

  Gonzalez, Emmanuel ^a   Ballana, Ester ^a   Clotet, Bonaventura ^a   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

fusion; fusion inhibitor; fusion peptide; gp41; resistance

Indexed keywords

ANTIVIRUS AGENT; BMS 155; ENFUVIRTIDE; GLYCOPROTEIN GP 41; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEVIRAPINE; PEPTIDE; PLERIXAFOR; UNCLASSIFIED DRUG; VIR 353; VIRUS INHIBITORY PEPTIDE; ZIDOVUDINE; ALPHA 1 ANTITRYPSIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT; VIR-353; VIRIP PEPTIDE, HUMAN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CROSS RESISTANCE; DRUG ACTIVITY; DRUG RESISTANCE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MUTAGENESIS; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECT; GENETICS; HUMAN; SITE DIRECTED MUTAGENESIS; VIRUS ENTRY;

ALPHA 1-ANTITRYPSIN; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; PEPTIDE FRAGMENTS; VIRUS INTERNALIZATION;

EID: 80051781764     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328348a733     Document Type: Article

References (39)

1. Este JA, Telenti A. HIV entry inhibitors. Lancet 2007;370:81-88. (Pubitemid 47018315)
2. Lederman M, Esté JA. Targeting a host element as a strategy to block HIV replication: is it nice to fool with Mother Nature? Curr Opin HIV AIDS 2009;4:79-81.
3. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185. (Pubitemid 36618128)
4. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-1441.
5. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 2010;85:91-100.
6. Este JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Res 2010;85:25-33.
7. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 2010;85:1-18.
8. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-340. (Pubitemid 39177450)
9. Menendez-Arias L. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res 2010;85:210-231.
10. He Y, Cheng J, Lu H, Li J, Hu J, Qi Z, et al. Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci U S A 2008;105:16332-16337.
11. He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X, et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008;283:11126-11134.
12. Welch BD, Francis JN, Redman JS, Paul S, Weinstock MT, Reeves JD, et al. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol 2010;84:11235-11244.
13. Welch BD, VanDemark AP, Heroux A, Hill CP, Kay MS. Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A 2007;104:16828-16833. (Pubitemid 350210950)
14. Cai L, Gochin M. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2007;51:2388-2395. (Pubitemid 47047315)
15. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001;75:10892-10905. (Pubitemid 33034579)
16. Broliden PA, Vongegerfelt A, Clapham P, Rosen J, Fenyo EM, Wahren B, Broliden K. Identification of human neutralization inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A 1992;89:461-465.
17. Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007;129:263-275. (Pubitemid 46574967)
18. Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, Barlos K, et al. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci Transl Med 2010;2:63re63.
19. Este JA. Virus entry as a target for anti-HIV intervention. Curr Med Chem 2003;10:1617-1632. (Pubitemid 37038589)
20. Menendez-Arias L, Este JA. HIV-resistance to viral entry inhibitors. Curr Pharm Des 2004;10:1845-1860. (Pubitemid 38647465)
21. Armand-Ugon M, Gutierrez A, Clotet B, Este JA. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res 2003;59:137-142. (Pubitemid 36929990)
22. Armand-Ugón M, Moncunill G, Mena MP, Gonzalez E, Ballana E, Clotet B, Esté JA. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. J Antimicrob Chemother 2010;65:417-424.
23. Este JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 1999;73:5577-5585. (Pubitemid 29274841)
24. Madani N, Perdigoto AL, Srinivasan K, Cox JM, Chruma JJ, LaLonde J, et al. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol 2004;78:3742-3752. (Pubitemid 38578378)
25. Pannecouque C, Daelemans D, De Clercq E. Tetrazoliumbased colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protocols 2008;3:427-434. (Pubitemid 351384256)
26. Moncunill G, Armand-Ugon M, Pauls E, Clotet B, Este JA. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS 2008;22:23-31. (Pubitemid 350294874)
27. Moncunill G, Armand-Ugon M, Clotet-Codina I, Pauls E, Ballana E, Llano A, et al. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026. Mol Pharmacol 2008;73:1264-1273. (Pubitemid 351439208)
28. Ballana E, Pauls E, Senserrich J, Clotet B, Perron-Sierra F, Tucker GC, Este JA. Cell adhesion through alpha V-containing integrins is required for efficient HIV-1 infection in macrophages. Blood 2009;113:1278-1286.
29. Gonzalez-Ortega E, Mena M-P, Permanyer M, Ballana E, Clotet B, Este JA. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block the fusion-active gp41 core formation. Antimicrob Agents Chemother 2010;54:4487-4492.
30. Armand-Ugon M, Clotet-Codina I, Tintori C, Manetti F, Clotet B, Botta M, Este JA. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. Virology 2005;343:141-149. (Pubitemid 41572240)
31. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992;66:6777-6780.
32. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999;99:103-115. (Pubitemid 29468634)
33. Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, Zhang H, et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 2005;102:14759-14764. (Pubitemid 41457129)
34. Kramer HB, Lavender KJ, Qin L, Stacey AR, Liu MK, di Gleria K, et al. Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. PLoS Pathog 2010;6:e1000893.
35. Mobley PW, Pilpa R, Brown C, Waring AJ, Gordon LM. Membrane-perturbing domains of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses 2001;17:311-327. (Pubitemid 32174814)
36. Manetti F, Tintori C, Armand-Ugon M, Clotet-Codina I, Massa S, Ragno R, et al. A combination of molecular dynamics and docking calculations to explore the binding mode of ADS-J1, a polyanionic compound endowed with anti-HIV-1 activity. J Chem Inf Model 2006;46:1344-1351. (Pubitemid 43999177)
37. Blanco J, Clotet-Codina I, Bosch B, Armand-Ugon M, Clotet B, Este JA. Multiparametric assay to screen and dissect the mode of action of antihuman immunodeficiency virus envelope drugs. Antimicrob Agents Chemother 2005;49:3926-3929. (Pubitemid 41233052)
38. Clotet-Codina I, Bosch B, Senserrich J, Fernandez-Figueras MT, Pena R, Ballana E, et al. HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection. Antiviral Res 2009;83:94-98.
39. Cherepanov P, Esté JA, Rando RF, Ojwang JO, Reekmans G, Steinfeld R, et al. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol Pharmacol 1997;52:771-780. (Pubitemid 27484169)